Thomson Reuters Names Most Promising Drugs of 2015

Annual forecast finds significant increase in the number of blockbusters set to enter this year's market

Philadelphia, PA, March 23, 2015 – – The Intellectual Property and Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report. The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach over $3 billion in sales by 2019. Thomson Reuters analysts utilized  CortellisTM Competitive Intelligence—the pharmaceutical industry's leading source for drug pipeline, deals, patents, and company content—to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2019.


The analysis spotlights the following 11 potential blockbusters, ranked by highest sales forecasts:


Drugs to Watch


Therapy Area

2019 Sales Forecast in U.S. $ billions)

Opdivo (nivolumab)

Bristol-Myers Squibb



Praluent (alirocumab)

Regeneron Pharmaceuticals and Sanofi



LCZ-696 (sacubitril and valsartan)


chronic heart failure


Ibrance (palbociclib)


breast cancer


lumacaftor plus ivacaftor

Vertex Pharmaceuticals

cystic fibrosis


Viekira Pak (veruprevir, ritonavir, ombitsvir and dasabuvir)


hepatitis C



Amgen and Astellas Pharma

hypercholesterolemia/ hypherlipidemia


Gardasil 9

Merck & Co.

HPV Vaccine



Otsuka Pharmaceutical and Lundbeck

schizophrenia and depression


Toujeo (new-formulation insulin glargine)




Cosentyx (secukinumab)


psoriasis and psoriatic arthritis



"This year's forecast identifies a substantial increase in the number of predicted blockbusters, inviting discussion around the current status of the blockbuster model," said Wendy Hamilton, global head of Life Sciences at Thomson Reuters. "As the pharmaceutical industry navigates constantly evolving revenue streams, this report serves as a valuable resource for identifying the therapies with the strongest sales potential."


To learn more about the year's most promising treatments, view 2015 Drugs to Watch. Learn more about Cortellis for Competitive Intelligence.




Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. For more information, go to


Jen Breen
+1 215 823 1791
[email protected]

Molly Malone
+1 215 823 3702
mol[email protected]



Suggested Articles

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.